ADCT Stock Overview
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.
ADC Therapeutics SA Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.82|
|52 Week High||US$32.00|
|52 Week Low||US$4.58|
|1 Month Change||-28.91%|
|3 Month Change||-43.56%|
|1 Year Change||-81.74%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-83.74%|
Recent News & Updates
ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
A committee of the European Medicines Agency (EMA) recommended the approval of ADC Therapeutics (NYSE:ADCT) and Swedish Orphan Biovitrum's (Sobi) Zynlonta (loncastuximab tesirine) in EU to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion by the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 2 trial called LOTIS-2. Approval decision from the European Commission's (EC), which generally follows the opinion of the CHMP, is expected in Q4 2022, the companies said in a Sept. 16 press release. ADC has license agreements for Zynlonta with Sobi and Mitsubishi Tanabe Pharma for certain regions.
ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Morgan Stanley downgraded ADC Therapeutics (NYSE:ADCT) to Equal Weight from Overweight in a research note issued on Friday. The investment bank lowered its price target to $11 from $17 on the commercial-stage biotechnology firm ADC Therapeutics (ADCT), citing Zynlonta penetration concerns. Stock is down 6% to trade at $6.16 on Friday. Seeking Alpha Quant Rating system assigns a Sell rating to ADCT, which sets the stock analysis stand apart from Wall Street's Strong Buy.
|ADCT||US Biotechs||US Market|
Return vs Industry: ADCT underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: ADCT underperformed the US Market which returned -23.2% over the past year.
|ADCT Average Weekly Movement||12.2%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ADCT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ADCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.
ADC Therapeutics SA Fundamentals Summary
|ADCT fundamental statistics|
Is ADCT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADCT income statement (TTM)|
|Cost of Revenue||US$160.21m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.34|
|Net Profit Margin||-199.01%|
How did ADCT perform over the long term?See historical performance and comparison